Ferrocifen Loaded Lipid Nanocapsules: A Promising Anticancer Medication against Multidrug Resistant Tumors

Area of Science:

• Medicinal Chemistry
• Nanotechnology
• Oncology

Background:

• Cancer cells exhibit resistance to conventional chemotherapeutics, necessitating novel treatment strategies.
• Ferrocifens, organometallic compounds derived from tamoxifen and ferrocene, display significant antiproliferative and cytotoxic effects.
• Lipid nanocapsules (LNCs) are solvent-free nanoparticles suitable for encapsulating hydrophobic drugs like ferrocifens.

Purpose of the Study:

• To review the application of ferrocifen-loaded LNCs as a nanomedicine for cancer therapy.
• To summarize the mechanisms of action of ferrocifens against cancer cells.
• To detail the formulation of LNCs and their in vivo efficacy.

Main Methods:

• Literature review of studies on ferrocifen-loaded LNCs over the past two decades.
• Analysis of in vitro and in vivo experimental data.
• Examination of ferrocifen's mechanism of action, including ferrocenyl quinone methide formation.

Main Results:

• Ferrocifen-loaded LNCs demonstrate efficacy against multidrug-resistant cancer cell lines, including glioblastoma, breast cancer, and melanoma.
• These nanoparticles show promise as a standalone therapy or in combination with other treatments.
• The formulation of LNCs facilitates the delivery of hydrophobic ferrocifen compounds.

Conclusions:

• Ferrocifen-loaded LNCs represent a promising nanomedicine approach for overcoming cancer drug resistance.
• Further research into their mechanisms and clinical application is warranted.
• This nanomedicine strategy holds potential for treating various aggressive cancers.